Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.04 Per Share

Share on StockTwits

Analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to report earnings of ($1.04) per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Spark Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.44) and the highest estimate coming in at ($0.39). Spark Therapeutics reported earnings per share of ($1.90) in the same quarter last year, which would suggest a positive year over year growth rate of 45.3%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that Spark Therapeutics will report full-year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($3.81) to $0.34. For the next financial year, analysts forecast that the firm will post earnings of ($3.71) per share, with EPS estimates ranging from ($5.35) to ($1.69). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.34). The firm had revenue of $25.19 million during the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%.

A number of research firms recently weighed in on ONCE. B. Riley began coverage on Spark Therapeutics in a report on Thursday, June 28th. They issued a “neutral” rating and a $74.00 price target on the stock. Cantor Fitzgerald set a $103.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, July 16th. BMO Capital Markets cut Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $60.00 price target on the stock. in a report on Tuesday, August 7th. Leerink Swann restated a “market perform” rating and issued a $55.00 price target (down previously from $74.00) on shares of Spark Therapeutics in a report on Tuesday, August 7th. Finally, Stifel Nicolaus lowered their price target on Spark Therapeutics from $76.00 to $68.00 and set a “buy” rating on the stock in a report on Wednesday, August 8th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $70.10.

Hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. lifted its stake in shares of Spark Therapeutics by 90.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,100 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 1,000 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Spark Therapeutics during the 2nd quarter worth $203,000. Cubist Systematic Strategies LLC purchased a new position in shares of Spark Therapeutics during the 2nd quarter worth $268,000. Bank of Montreal Can lifted its stake in shares of Spark Therapeutics by 1,045.4% during the 3rd quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 2,969 shares during the period. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Spark Therapeutics during the 1st quarter worth $240,000.

Shares of ONCE traded down $0.12 on Friday, reaching $46.03. The stock had a trading volume of 308,187 shares, compared to its average volume of 643,953. The stock has a market cap of $1.72 billion, a P/E ratio of -6.03 and a beta of 2.24. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $96.59.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Story: Using the New Google Finance Tool

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.